A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

Phase 1 Recruiting 80 enrolled Jemincare Zhejiang Hangyu Pharmaceutical Co., Ltd. · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.

Timeline

Start: 2024-03-14
Primary completion: 2026-05-31
Completion: 2027-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JMKX003948	Unknown	—	—

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

Summary

Timeline

Drugs

Indications